Rockefeller Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Rockefeller Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100	Closed	-$1K	–	3992
2022 Q4	$1K	Sell	100 -945	-90%	-$21.6K	﹤0.01%	3784
2022 Q3	$28K	Buy	1,045 +406	+64%	+$8.24K	﹤0.01%	2631
2022 Q2	$8K	Buy	639 +594	+1,320%	+$9.14K	﹤0.01%	3266
2022 Q1	$0	Hold	45	–	–	﹤0.01%	4106
2021 Q4	$0	Sell	45 -472	-91%	-$7.87K	﹤0.01%	4025
2021 Q3	$14K	Hold	517	–	–	﹤0.01%	2747
2021 Q2	$15K	Hold	517	–	–	﹤0.01%	2621
2021 Q1	$14K	Buy	+517	New	+$14.3K	﹤0.01%	2459
2020 Q4	–	Sell	-314	Closed	-$7K	–	3036
2020 Q3	$7K	Buy	314 +115	+58%	+$3.02K	﹤0.01%	2133
2020 Q2	$5K	Sell	199 -106	-35%	-$2.09K	﹤0.01%	2119
2020 Q1	$5K	Buy	+305	New	+$6.31K	﹤0.01%	1977

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Rockefeller Capital Management's RVNC Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2023, closing a stake of 100 shares — an estimated $1K sold.

Rockefeller Capital Management first reported a position in RVNC in Q1 2020 and held it in 11 quarters. The position peaked at $28K in Q3 2022. 216 funds tracked by Wall St. Rank hold RVNC as of Q1 2023.

Rockefeller Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Rockefeller Capital Management sold 100 Revance Therapeutics, Inc. shares in Q1 2023, an estimated $1K.
Rockefeller Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2020 and held it in 11 quarters.
Rockefeller Capital Management's Revance Therapeutics, Inc. position peaked at $28K in Q3 2022.
216 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.